Cellestia is a biopharmaceutical company developing innovative first-in-class anti-cancer drugs. Our clinical stage lead compound CB-103 is a selective oncogene transcription factor inhibitor for treatment of currently untreatable cancers driven by oncogenic activation of NOTCH.

Cooperation possibilities

R&D, co-development, licensing

Location

Hochbergerstr. 60C, 4057 Basel, Switzerland

Facts & figures
  • Type of organization

    Private company

  • Year of foundation

    2014

  • Number of employees in Switzerland

    1-9

Key business